IP Library › Granted Patent US 7,528,155
Granted Patent B2
US 7,528,155 · App. 11/042,565 · Granted May 5, 2009

Indazole derivatives as inhibitors of hormone sensitive lipase

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,528,155
App. No.
11/042,565
Granted
May 5, 2009
Kind
B2
Abstract

The present invention relates to indazole derivatives of the general formulae I or II having the meanings indicated in the description, to the pharmaceutically useful salts thereof and the use thereof as drugs.

Claims (25)

1. An indazole derivative of the formula II

in which the meanings are:

W is —(C═O);

X is C—R;

Y is —O—;

R is hydrogen, halogen, (C 1 -C 6 )-alkyl, (C 1 -C 3 )-alkyloxy-(C 1 -C 3 )-alkylene, hydroxy, (C 1 -C 6 )-alkylmercapto, amino, (C 1 -C 6 )-alkylamino, di-(C 2 -C 12 )-alkylamino, mono-(C 1 -C 6 )-alkylaminocarbonyl, di-(C 2 -C 8 )-alkylaminocarbonyl, COOR4, cyano, trifluoromethyl, (C 1 -C 6 )-alkylsulfonyl, (C 1 -C 6 )-alkylsulfinyl, aminosulfonyl, nitro, pentafluorosulfanyl, (C 6 -C 10 )-aryl, CO—NR2R3, O—CO—NR2R3, O—CO—(C 1 -C 6 )-alkylene-CO—O—(C 1 -C 6 )-alkyl, O—CO—(C 1 -C 6 )-alkylene-CO—OH, O—CO—(C 1 -C 6 )-alkylene-CO—NR2R3 or unsubstituted or mono- or poly- F-substituted (C 1 -C 6 )-alkyloxy;

R1 is H, (C 1 -C 6 )-alkyl or benzyl;

R2 and R3 together with the nitrogen atom carrying them form piperidine which optionally comprises the atomic member CHR5 in position 4;

R4 is hydrogen, (C 1 -C 6 )-alkyl or benzyl;

R5 is (C 1 -C 6 )-alkyl, halogen, trifluoromethyl, or cyclopropylene;

and the physiologically tolerated salts thereof as well as its tautomeric forms.

2. The indazole derivative of claim 1 , wherein

X in position 4, 5 and 7 is C—R with R=hydrogen.

3. The indazole derivative of claim 1 , wherein

W is —(C═O)—;

X is C—R;

Y is —O—;

R is hydrogen, halogen, (C 1 -C 6 )-alkyl, hydroxy, amino, COOR4, trifluoromethyl, (C 1 -C 6 )-alkylsulfonyl, nitro, pentafluorosulfanyl, (C 6 -C 10 )-aryl, CO—NR2R3, O—CO—NR2R3 or O—CO—(C 1 -C 6 )-alkylene-CO—O—(C 1 -C 6 )-alkyl;

R1 is H, (C 1 -C 6 )-alkyl or benzyl;

R2 and R3 together with the nitrogen atom carrying them form piperidine which optionally comprises the atomic member CHR5 in position 4;

R4 is hydrogen, (C 1 -C 6 )-alkyl or benzyl; and

R5 is (C 1 -C 6 )-alkyl, halogen, trifluoromethyl or cyclopropylene.

4. The indazole derivative of claim 1 , wherein

NR2R3 is piperidine which comprises the atomic member CHR5 in position 4.

5. A pharmaceutical composition comprising one or more of the indazole derivatives of claim 1 and a pharmaceutically acceptable carrier.